Systematic Review
Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. May 31, 2019; 7(5): 224-233
Published online May 31, 2019. doi: 10.13105/wjma.v7.i5.224
Table 1 Clinical characteristics and location in selected patients with extra-gastrointestinal stromal tumor of the liver
Ref .Yr Age / Sex Country Presentation Location Size (cm) Multifocal Hu et al [20 ] 2018 79/F China Epigastric discomfort RL 3.2 No Joyon et al [21 ] 2018 56/M France Abdominal pain Bilobar (Segments VII/VIII and LL) 10 Yes 2018 59/F France Abdominal pain, weight loss RL 23 No Carrillo et al [22 ] 2017 41/M Spain Abdominal pain, weight loss RL (S. V-VI) 20 No Lok et al [23 ] 2017 50/F China Abdominal pain RL 15 Yes Cheng et al [24 ] 2016 63/M China No symptoms RL 15 No Nagai et al [25 ] 2016 70/F Japan Follow-up gastric cancer, No symptoms LL 6 No Liu et al [26 ] 2016 NA China NA NA NA NA Wang et al [27 ] 2016 61/M China No symptoms Caudate lobe 7.3 No Liu et al [28 ] 2016 56/F China No symptoms LL + Pancreas 2.2 No Su et al [29 ] 2015 65/M Taiwan Malaise, loss of apetite, abdominal pain LL 12 No Bhoy et al [3 ] 2014 41/F India Abdominal pain, weight loss RL (S.VI-VI) I 15 Yes Lin et al [30 ] 2015 67/F China No symptoms RL 7.4 No Mao et al [31 ] 2015 60/F China No symptoms Bilobar (S I, IV, V, VIII) 12.8 No Kim et al [32 ] 2014 71/M Korea Study for early gastric cancer, No symptoms LL 7 No Louis et al [33 ] 2014 55/F India Abdominal pain, loss of apetite Bilobar (SII, III, VI, VIII) 14.5 Yes Zhou et al [34 ] 2014 56/M China No symptoms RL 10 No Li et al [35 ] 2012 53/M China Abdominal discomfort RL 20 No Yamamoto et al [36 ] 2010 70/M Japan Loss of apetite (12 years after gastric cancer) LL 20 No Luo et al [37 ] 2009 17/M China No symptoms RL 5 No Ochiai et al [38 ] 2009 30/M Japan Abdominal fullnes Bilobar 27 No De Chiara et al [1 ] 2006 37/M Italy No symptoms RL (SV) 18 No Hu et al [6 ] 2003 79/F USA Shortness of breath, pleuritic chest pain RL 15 No
Table 2 Diagnostic characteristics in selected patients with extra-gastrointestinal stromal tumor of the liver
Ref .Yr Age / Sex Endoscopy Imaging Biopsy Hu et al [20 ] 2018 79/F Yes (no findings) CT No Joyon et al [21 ] 2018 56/M NA CT Percutaneous 2018 59/F Yes (no findings) CT Guided Carrillo et al [22 ] 2017 41/M Yes (no findings) CT / MRI No Lok et al [23 ] 2017 50/F Yes (no findings) CT No Cheng et al [24 ] 2016 63/M NA CT No Nagai et al [25 ] 2016 70/F Yes (no findings) CT / MRI No Liu et al [26 ] 2016 NA NA NA NA Wang et al [27 ] 2016 61/M NA CT No Liu et al [28 ] 2016 56/F NA CT Surgical Su et al [29 ] 2015 65/M NA CT CT-guided Bhoy et al [3 ] 2014 41/F NA US/ CT FNA Lin et al [30 ] 2015 67/F Yes (no findings) CT No Mao et al [31 ] 2015 60/F Yes (no findings) CT / MRI No Kim et al [32 ] 2014 71/M Early gastric cancer CT / MRI No Louis et al [33 ] 2014 55/F NA CT US-FNA/CT-FNA Zhou et al [34 ] 2014 56/M Yes (no findings) NA No Li et al [35 ] 2012 53/M NA CT US-FNAB Yamamoto et al [36 ] 2010 70/M NA CT No Luo et al [37 ] 2009 17/M NA CT/US US-FNA Ochiai et al [38 ] 2009 30/M NA CT/ MRI No De Chiara et al [1 ] 2006 37/M NA CT No Hu et al [6 ] 2003 79/F NA CT No
Table 3 Treatment and adjuvant treatment in selected patients with extra-gastrointestinal stromal tumor of the liver
Ref .Yr Age / Sex Treatment Adjuvant imatinib mesylate Hu et al [20 ] 2018 79/F Curative surgical resection Yes Joyon et al [21 ] 2018 56/M OLT No 2018 59/F Refused surgery: imatinib mesylate No Carrillo et al [22 ] 2017 41/M Segmentectomy V-VI Yes Lok et al [23 ] 2017 50/F Right hepatectomy Yes Cheng et al [24 ] 2016 63/M Right hepatectomy Yes Nagai et al [25 ] 2016 70/F Left lateral segmentectomy No Liu et al [26 ] 2016 NA NA NA Wang et al [27 ] 2016 61/M Caudate lobe resection No Liu et al [28 ] 2016 56/F Microwave ablation Yes Su et al [29 ] 2015 65/M Irresecable: imatinib mesylate No Bhoy et al [3 ] 2014 41/F Right hepatectomy Yes Lin et al [30 ] 2015 67/F Surgical excision Yes Mao et al [31 ] 2015 60/F ECHRA Yes Kim et al [32 ] 2014 71/M Left lateral segmentectomy+excision of 1 intrabadominal nodule+total gastrectomy NA Louis et al [33 ] 2014 55/F Segmentectomy III and atypical resection (segments II, VI and VIII) Yes Zhou et al [34 ] 2014 56/M Anterior and median segmentectomy No Li et al [35 ] 2012 53/M Refused treatment No Yamamoto et al [36 ] 2010 70/M Left hepatectomy NA Luo et al [37 ] 2009 17/M RFA NA Ochiai et al [38 ] 2009 30/M L-Trisegmentectomy Yes De Chiara et al [1 ] 2006 37/M NA No Hu et al [6 ] 2003 79/F Right lobectomy NA
Table 4 Pathological, immunohistochemical and molecular findings, and risk of malignancy according to Fletcher
et al [
2 ]
Ref .Yr Age / Sex Cell type Molecular analysis Mitotic count (nº / 50 HPF) IH Risk of malignancy Hu et al [20 ] 2018 79/F Spindle cells NA NA CD117+, CD34+ NA Joyon et al [21 ] 2018 56/M Spindle cells NA 8 CD117+, CD 34+ High risk 2018 59/F Mixed (spindle and epithelioid) 6 bp deletion in KIT exon 11 42 CD117+ High risk Carrillo et al [22 ] 2017 41/M Spindle cells 9 deletion in KIT 5 CD 117+, CD 34- High risk Lok et al [23 ] 2017 50/F Spindle cells NA 70 CD117+, CD 34+ High risk Cheng et al [24 ] 2016 63/M Spindle cells NA >5 CD 117 +, CD 34- High risk Nagai et al [25 ] 2016 70/F Spindle cells NA 40 CD117+, CD 34+ High risk Liu et al [26 ] 2016 NA NA NA NA NA NA Wang et al [27 ] 2016 61/M Spindle cells NA NA CD117+/CD34+ High risk Liu et al [28 ] 2016 56/F Spindle cells NA 2 CD117+ Low risk Su et al [29 ] 2015 65/M Spindle cells NA 5 CD117+, CD 34- High risk Bhoy et al [3 ] 2014 41/F NA NA NA CD 117+ High risk Lin et al [30 ] 2015 67/F Mixed (spindle and epithelioid) Mutation in exon 11 8 CD117+, CD 34+ High risk Mao et al [31 ] 2015 60/F Spindle cells Mutation in exon 11 >10 CD 117+, CD 34 - High risk Kim et al [32 ] 2014 71/M Spindle cells NA 30-32 CD117+ High risk Louis et al [33 ] 2014 55/F Spindle cells NA 10 CD117+ High risk Zhou et al [34 ] 2014 56/M Spindle cells NA <5 CD117+/CD34+ Intermediate Li et al [35 ] 2012 53/M Spindle cells NA NA CD117+, CD34+ High risk Yamamoto et al [36 ] 2010 70/M Epithelioid cells mutation PDGFRA exon 12 1 CD 117-/CD34+ High risk Luo et al [37 ] 2009 17/M Spindle cells NA 0 CD117+, CD 34+ Low risk Ochiai et al [38 ] 2009 30/M Mixed (spindle and epithelioid) No mutation at exon 11 75 CD117+, CD 34+ High risk De Chiara et al [1 ] 2006 37/M Spindle cells NA 20 CD117+, CD 34+ High risk Hu et al [6 ] 2003 79/F Spindle cells NA 20 CD117+, CD 34+ Low risk
Table 5 Outcome and follow-up in selected patients with EGIST of the liver
Ref .Yr Outcome Follow-up (mo) Hu et al [20 ] 2018 NA NA Joyon et al [21 ] 2018 Local recurrence (12 yr) 252 2018 DF 18 Carrillo et al [22 ] 2017 DF 18 Lok et al [23 ] 2017 Brain metastasis (6 mo) 6 Cheng et al [24 ] 2016 DF 30 Nagai et al [25 ] 2016 DF 10 Liu et al [26 ] 2016 NA NA Wang et al [27 ] 2016 DF 12 Liu et al [28 ] 2016 Abdominal metastasis 17 Su et al [29 ] 2015 Progression of disease (died 6 mo) 6 Bhoy et al [3 ] 2014 DF 5 Lin et al [30 ] 2015 Hepatic recurrence (24 mo) 72 Mao et al [31 ] 2015 DF 12 Kim et al [32 ] 2014 NA NA Louis et al [33 ] 2014 DF 6 Zhou et al [34 ] 2014 DF 12 Li et al [35 ] 2012 NA NA Yamamoto et al [36 ] 2010 NA NA Luo et al [37 ] 2009 DF 3 Ochiai et al [38 ] 2009 Hepatic recurrence, submucosal gastric tumor (24 mo) 25 De Chiara et al [1 ] 2006 Lung mestastasis (14 mo) 39 Hu et al [6 ] 2003 Portal lymph node mestastasis (16 mo) 16